Oxaliplatin plus Vinorelbine in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

DENG Ying ,  HU Honglin , PAN Haixia , REN Gang , YANG Lan , ZHU Xueqiang , LIU Hao

Sichuan Provincial People’s Hospital, Chengdu 610072, China;

Corresponding author：

HU Honglin, Email: cdlvdy@qq.com

Keywords：

Oxaliplatin; Vinorelbine; Advanced non-small cell lung cancer; Treatment; Systematic review

DOI：

10.7507/1672-2531.20100457

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To assess clinical efficacy and safety of Oxaliplatin plus Vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
Methods 　We used the methods of Cochrane reviews, electronically searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2008), MEDLINE (1966 to April 2008), EMbase (1984 to Dec. 2006), Cancerlit (1996 to Dec. 2005), CBM (1978 to April 2008), CNKI (1994 to April 2008), VIP (1989 to April 2008), and handsearched 15 Chinese medical core journals, to collect randomized controlled trials (RCTs) of Oxaliplatin combined with Vinorelbine in the treatment of advanced NSCLC. RCTs were included according to the inclusion and exclusion criteria, the quality of included trials was evaluated and RevMan 4.2.8 software was used for metaanalyses after the extraction of the data.
Results 　Seventeen RCTs involving 1 399 patients with advanced NSCLC were included. All of them reported the use of a random method, but with no detailed reports of allocation concealment and whether the blind method was used. The results of meta-analyses showed that NO program (vinorelbine + oxaliplatin) and NP program (vinorelbine + cisplatin) were similar in efficient rate (RR=0.97, 95%CI 0.85 to 1.10) and 1-year survival rate (RR=0.82, 95%CI 0.66 to 1.03). Compared with NP program, NO program induced lower III-IV degree of nausea and vomiting response (RR=0.20, 95%CI 0.14 to 0.28), III-IV degree of leukopenia reaction (RR=0.64, 95%CI 0.52 to 0.79), and I-II degree of renal damage RR=0.27, 95%CI 0.11 to 0.60) after chemotherapy. No study reported treatmentrelated death.
Conclusion 　Oxaliplatin and Cisplatin plus Vinorelbine are similar in efficacy in the treatment of advanced NSCLC. Oxaliplatin plus Vinorelbine could be used as a chemotherapy of advanced NSCLC because of its better tolerance and more liability to be accepted by patients. However, highly-potential selection bias and measurement bias would affect the demonstration level of the outcome, so more high-quality double-blind RCTs are needed.

Citation： DENG Ying,HU Honglin,PAN Haixia,REN Gang,YANG Lan,ZHU Xueqiang,LIU Hao. Oxaliplatin plus Vinorelbine in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2010, 10(5): 609-617. doi: 10.7507/1672-2531.20100457 Copy

1.	American Cancer Society: Cancer Facts and Figures 2006. Atlanta, Ga; American Cancer Society, 2006. Also available online, Last accessed August 7, 2006.
2.	中国抗癌协会临床肿瘤学协作专业委员会, 2006. Also available online (www.csco.net.cn).
3.	Aymond E, Chaney SG, Taama A, et al. Oxalilatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9: 1053-1071.
4.	Faivre S, Le Chevalier T, Monnerat C, et al. Phase I-II and pharmacokinetic study of gemcitane combined with oxaliplatin in platents with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol, 2002, 13(9): 1479-1489.
5.	Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewer’s Handbook 4.2.2 (updated March 2004). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2004.
6.	Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med, 2002, 21(11): 1539-1558.
7.	Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,graphical test. BMJ, 1997, 315(7109): 629-634.
8.	罗涛, 陈玉玲, 李斯南. 奥沙利铂联合去甲长春花碱治疗晚期非小细胞肺癌38例临床观察. 临床肿瘤学杂志, 2004, 9(3): 286-287.
9.	吴田, 高锦秀, 魏军功, 等. 草酸铂加长春瑞滨治疗晚期非小细胞肺癌临床观察. 肿瘤, 2007, 27(6): .
10.	冯永梅. 奥沙利铂联合长春瑞滨与顺铂联合长春瑞滨治疗非小细胞肺癌的比较.《中国保健》医学研究版, 2007, 15(11): 180-181.
11.	刘敏知, 刘晖群. 奥沙利铂联合长春瑞滨治疗晚期非小细胞肺癌的临床研究. 江西医药, 2005, 40(12): 835-836.
12.	任莉, 朱江, 勾红峰, 等. 奥沙利波及顺铂联合长春瑞滨治疗晚期非小细胞肺癌随机对照临床研究. 中国肺癌杂志, 2005, 8(6): 538-542.
13.	张湘茹, 侯梅, 孙京栋, 等. 奥沙利铂加长春瑞滨与顺铂加长春瑞滨治疗晚期非小细胞肺癌的随机对照研究. 中华肿瘤杂志, 2005, 27(12): 743-747.
14.	王晓瑜, 杨峰. 奥沙利铂联合长春瑞滨治疗非小细胞肺癌30例. 郑州大学学报(医学版), 2006, 41(4): 804-805.
15.	姚文秀, 周行, 魏阳, 等. 奥沙利铂联合长春瑞滨治疗晚期非小细胞肺癌疗效观察. 中国肺癌杂志, 2005, 8(3): 227-230.
16.	刘震天, 陈颖兰. 奥沙利铂联合顺铂、卡铂、奥沙利铂在治疗晚期非小细胞肺癌的比较. 实用临床医学, 2006, 7(10): 61-63.
17.	李勇诚, 赵云娟, 邬海燕, 等. 长春瑞滨联合奥沙利铂治疗非小细胞肺癌. 中国肺癌杂志, 2004, 14(4): 373-375.
18.	王晓华, 侯梅, 曹丹. 长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的随机对照临床研究. 中国肺癌杂志, 2006, 9(1): 71-73.
19.	徐敬根, 张静, 易琼. 顺铂与草酸铂联合长春瑞滨治疗晚期非小细胞肺癌比较研究. 泸州医学院学报, 2008, 31(3): 290-293.
20.	刘坤, 赵金奇, 王羽丰. 长春瑞滨加草酸铂和顺铂治疗晚期非小细胞肺癌的比较. 实用癌症杂志, 2006, 21(3): 283-285.
21.	雷莉莉. 以草酸铂为主治疗52例晚期非小细胞肺癌的临床观察. 中国肺癌杂志, 2005, 8(1): 68.
22.	董粉英, 刘洪, 庞伟, 等. 长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌. 实用医学杂志, 2008, 24(1): 168-169.
23.	黄平, 罗展雄, 朱州. 长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的临床观察. 临床肺科杂志, 2006, 11(3): 284-285.
24.	卢进, 李晓, 陈萍, 等. 长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的临床观察. 四川省肿瘤防治, 2005, 18(3): 148-150.
25.	李新文. NO方案治疗非小细胞肺癌的疗效观察. 中原医刊, 2006, 33(7): 187-188.
26.	高建飞, 张新华, 王军, 等. NO和NP方案治疗晚期非小细胞肺癌的前瞻随机研究. 癌症, 2005, 24(8): 990-993.
27.	Monnet L, Soulie P, De Cremoux H, et al. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small cell lung cancer. J Clin Oncol, 2001, 19(3): 458-463.
28.	Trédaniel J, Becht C, Bekradda M, et al. An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer, 2008, 6(5): 15-19.

1. American Cancer Society: Cancer Facts and Figures 2006. Atlanta, Ga; American Cancer Society, 2006. Also available online, Last accessed August 7, 2006.
2. 中国抗癌协会临床肿瘤学协作专业委员会, 2006. Also available online (www.csco.net.cn).
3. Aymond E, Chaney SG, Taama A, et al. Oxalilatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9: 1053-1071.
4. Faivre S, Le Chevalier T, Monnerat C, et al. Phase I-II and pharmacokinetic study of gemcitane combined with oxaliplatin in platents with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol, 2002, 13(9): 1479-1489.
5. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewer’s Handbook 4.2.2 (updated March 2004). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2004.
6. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med, 2002, 21(11): 1539-1558.
7. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,graphical test. BMJ, 1997, 315(7109): 629-634.
8. 罗涛, 陈玉玲, 李斯南. 奥沙利铂联合去甲长春花碱治疗晚期非小细胞肺癌38例临床观察. 临床肿瘤学杂志, 2004, 9(3): 286-287.
9. 吴田, 高锦秀, 魏军功, 等. 草酸铂加长春瑞滨治疗晚期非小细胞肺癌临床观察. 肿瘤, 2007, 27(6): .
10. 冯永梅. 奥沙利铂联合长春瑞滨与顺铂联合长春瑞滨治疗非小细胞肺癌的比较.《中国保健》医学研究版, 2007, 15(11): 180-181.
11. 刘敏知, 刘晖群. 奥沙利铂联合长春瑞滨治疗晚期非小细胞肺癌的临床研究. 江西医药, 2005, 40(12): 835-836.
12. 任莉, 朱江, 勾红峰, 等. 奥沙利波及顺铂联合长春瑞滨治疗晚期非小细胞肺癌随机对照临床研究. 中国肺癌杂志, 2005, 8(6): 538-542.
13. 张湘茹, 侯梅, 孙京栋, 等. 奥沙利铂加长春瑞滨与顺铂加长春瑞滨治疗晚期非小细胞肺癌的随机对照研究. 中华肿瘤杂志, 2005, 27(12): 743-747.
14. 王晓瑜, 杨峰. 奥沙利铂联合长春瑞滨治疗非小细胞肺癌30例. 郑州大学学报(医学版), 2006, 41(4): 804-805.
15. 姚文秀, 周行, 魏阳, 等. 奥沙利铂联合长春瑞滨治疗晚期非小细胞肺癌疗效观察. 中国肺癌杂志, 2005, 8(3): 227-230.
16. 刘震天, 陈颖兰. 奥沙利铂联合顺铂、卡铂、奥沙利铂在治疗晚期非小细胞肺癌的比较. 实用临床医学, 2006, 7(10): 61-63.
17. 李勇诚, 赵云娟, 邬海燕, 等. 长春瑞滨联合奥沙利铂治疗非小细胞肺癌. 中国肺癌杂志, 2004, 14(4): 373-375.
18. 王晓华, 侯梅, 曹丹. 长春瑞滨联合顺铂与长春瑞滨联合奥沙利铂治疗晚期NSCLC的随机对照临床研究. 中国肺癌杂志, 2006, 9(1): 71-73.
19. 徐敬根, 张静, 易琼. 顺铂与草酸铂联合长春瑞滨治疗晚期非小细胞肺癌比较研究. 泸州医学院学报, 2008, 31(3): 290-293.
20. 刘坤, 赵金奇, 王羽丰. 长春瑞滨加草酸铂和顺铂治疗晚期非小细胞肺癌的比较. 实用癌症杂志, 2006, 21(3): 283-285.
21. 雷莉莉. 以草酸铂为主治疗52例晚期非小细胞肺癌的临床观察. 中国肺癌杂志, 2005, 8(1): 68.
22. 董粉英, 刘洪, 庞伟, 等. 长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌. 实用医学杂志, 2008, 24(1): 168-169.
23. 黄平, 罗展雄, 朱州. 长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的临床观察. 临床肺科杂志, 2006, 11(3): 284-285.
24. 卢进, 李晓, 陈萍, 等. 长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的临床观察. 四川省肿瘤防治, 2005, 18(3): 148-150.
25. 李新文. NO方案治疗非小细胞肺癌的疗效观察. 中原医刊, 2006, 33(7): 187-188.
26. 高建飞, 张新华, 王军, 等. NO和NP方案治疗晚期非小细胞肺癌的前瞻随机研究. 癌症, 2005, 24(8): 990-993.
27. Monnet L, Soulie P, De Cremoux H, et al. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small cell lung cancer. J Clin Oncol, 2001, 19(3): 458-463.
28. Trédaniel J, Becht C, Bekradda M, et al. An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer, 2008, 6(5): 15-19.

Chinese Journal of Evidence-Based Medicine

Oxaliplatin plus Vinorelbine in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content